FZD1: As a Novel Prognostic Marker for Renal Clear Cell Carcinoma, is Associated with Tumor Immunoinfiltration

Min Luo^{1, 2}, Yin Wang^1, and Pei Feng Li^1,

¹Institute for Translational Medicine, Qingdao University, Qingdao 266000, China

²The Third Affiliated Hospital of Zunyi Medical University, The First People's Hospital of Zunyi, Zunyi, Guizhou, 563000, China

Cite this paper:
Min Luo, Yin Wang and Pei Feng Li. FZD1: As a Novel Prognostic Marker for Renal Clear Cell Carcinoma, is Associated with Tumor Immunoinfiltration. Journal of Food and Nutrition Research. 2024; 12(3):151-159. doi: 10.12691/jfnr-12-3-7

Abstract

Renal clear cell carcinoma (ccRCC) is one of the most prevalent and aggressive histological subtypes of all renal cell carcinomas (RCCS) and is a metabolically abnormal cancer. Advanced ccRCC usually has a poor prognosis. Therefore, appropriate tumor markers need to be developed to predict the treatment, prognosis, and progression of ccRCC. Recombinant Frizzled Homolog 1 (FZD1) is a receptor for the Wnt signaling pathway, and overexpression of FZD1 has been detected in many cancer tissues and cells, leading to tumor development and drug resistance. However, its expression status and prognostic value in renal carcinoma remain unclear. Therefore, the purpose of this study was to explore the relationship between clinical features, overall survival, immune infiltration, and prognostic risk in patients with FZD1 and ccRCC through bioinformatics. ccRCC RNA-seq FPKM format data and clinical data were downloaded from TCGA database, and the correlation between FZD1 and ccRCC was evaluated by Cox and Logistic analysis. The results showed that the expression of FZD1 in renal carcinoma tissues was higher than that in normal tissues (P＜0.001); The ROC curve showed that FZD1 had high diagnostic value (AUC = 0.877). High expression of FZD1 is associated with immune status of renal clear cell carcinoma. These data indicate that the expression status of FZD1 has diagnostic and prognostic value in patients with ccRCC, and is a feasible potential novel prognostic marker for ccRCC, and may also be used as a potential therapeutic target for alleviating ccRCC patients.

Keywords:
FZD1 ccRCC Immunoinfiltration Biomarker

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Huang JJ, Hsieh JJ. The therapeutic landscape of renal cell carcinoma: From the dark age to the golden age. Semin Nephrol. (2020) 40(1): 28-41.
[2]	Morgantetti G, Ng KL, Samaratunga H, et al. Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis. Transl Androl Urol. (2019) 8(Suppl 2): S147-55.
[3]	Ahn T, Roberts MJ, Abduljabar A, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol (2019) 21(5): 799-807.
[4]	Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009; 373: 1119-32.
[5]	Yu J, Mao W, Xu B, et al. Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients. Cancer Med. 2021 Apr;10(7): 2359-2369.
[6]	Wang S, Zhang L, Yu Z, et al. Identification of a Glucose Metabolism-related Signature for prediction of Clinical Prognosis in Clear Cell Renal Cell Carcinoma. J Cancer. 2020 Jun 21;11(17): 4996-5006.
[7]	Makhov P, Joshi S, Ghatalia P, et al. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Molecular Cancer Therapeutics . 2018;17(7): 1355-1364.
[8]	Raghubar AM, Roberts MJ, Wood S, et al. Cellular milieu in clear cell renal cell carcinoma. Front Oncol. 2022 Oct 14; 12: 943583.
[9]	Liu T, Yang K, Chen J, et al. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity. Biomolecules. 2023 Feb 8; 13(2): 326.
[10]	Goncalves G, Mullan KA, Duscharla D, et al. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation. Front Immunol. 2021 Apr 22; 12: 645770.
[11]	Terrén I, Orrantia A, Vitallé J, et al. NK Cell Metabolism and Tumor Microenvironment. Front Immunol. 2019 Sep 24; 10: 2278.
[12]	Xiao Y, Yang J, Yang M, et al. Comprehensive analysis of 7-methylguanosine and immune microenvironment characteristics in clear cell renal cell carcinomas. Front Genet. 2022 Aug 8; 13: 866819.
[13]	Sagara N, Kirikoshi H, Terasaki H, et al. FZD4S, a splicing variant of frizzled-4, encodes a soluble-type positive regulator of the WNT signaling pathway. Biochem Biophys Res Commun. 2001 Apr 6; 282(3): 750-6.
[14]	Zhang YP, Gao D, Wu P. [RBM38 Mediates the Proliferation of Acute Myeloid Leukemia Cells HL-60 by Regulating FZD1 mRNA Stability]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Dec; 29(6): 1775-1779. Chinese.
[15]	Wang Z, Song K, Zhao W, et al. Dendritic cells in tumor microenvironment promoted the neuropathic pain via paracrine inflammatory and growth factors. Bioengineered. 2020 Dec; 11(1): 661-678.
[16]	Ghatak S, Hascall VC, Markwald RR, et al. FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells. Int J Mol Sci. 2021 Jan 13; 22(2): 753.
[17]	Flahaut M, Meier R, Coulon A, et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene. 2009 Jun 11; 28(23): 2245-56.
[18]	Dagher J, Delahunt B, Rioux-Leclercq N, et al. Percentage grade 4 tumour predicts outcome for clear cell renal cell carcinoma. Pathology. 2019 Jun; 51(4): 349-352.
[19]	Han W, Fan B, Huang Y, et al. Construction and validation of a prognostic model of RNA binding proteins in clear cell renal carcinoma. BMC Nephrol. 2022 Jul 15; 23(1): 252.
[20]	Krishna C, DiNatale RG, Kuo F, et al. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell. 2021 May 10; 39(5): 662-677.
[21]	Wang R, Wang X, Zhang J, et al. LINC00942 Promotes Tumor Proliferation and Metastasis in Lung Adenocarcinoma via FZD1 Upregulation. Technol Cancer Res Treat. 2021 Jan-Dec; 20: 1533033820977526.